Skip to main content
KRRO
NASDAQ Life Sciences

Korro Bio swaps 1M Venrock shares for pre-funded warrants, reports $137.9M cash and pipeline advances

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$11.5
Mkt Cap
$165.86M
52W Low
$5.204
52W High
$55.89
52W Position info
121% above low
Off High info
79% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

KRRO has more than doubled off its 52-week low of $5.204.

Summary

Korro Bio exchanged 1 million Venrock common shares for pre-funded warrants, leaving the fully diluted share count unchanged. The company also reported Q2 2026 results with $137.9 million in cash and a runway into 2H 2028, alongside pipeline progress for KRRO-121 and KRRO-111.


Key Events · Financing and Capital Events · KRRO

  • Venrock Share-for-Warrant Exchange

    Venrock surrendered 1,000,000 common shares for no consideration and received pre-funded warrants to purchase 1,000,000 shares at $0.001 per share, with no expiration. Post-exchange, outstanding shares drop to 13,725,646, but unexercised pre-funded warrants total 4,148,836, leaving fully diluted economics unchanged.

  • Q2 2026 Financial Results

    Cash, cash equivalents, and marketable securities were $137.9 million as of June 30, 2026. Net loss was $18.9 million for the quarter, with R&D expenses of $13.6 million and G&A of $6.5 million. Cash runway extends into the second half of 2028.

  • KRRO-121 Regulatory Progress

    KRRO-121 received EMA Orphan Drug Designation for urea cycle disorders and remains on track to commence a first-in-human clinical trial in the second half of 2026.

  • KRRO-111 Development Candidate Nomination

    Korro nominated KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency (AATD), a GalNAc-conjugated oligonucleotide delivered subcutaneously, with preclinical data showing over 90% RNA editing and near-complete reduction of pathogenic Z-AAT protein.


Analysis · KRRO · Life Sciences

In a share-for-warrant exchange with Venrock, Korro Bio surrendered 1 million common shares and issued pre-funded warrants covering the same number of shares. While the outstanding share count drops by 1 million to 13.7 million, the warrants—exercisable at $0.001 with no expiration—preserve the same economic exposure. The net result is a cosmetic reduction in shares outstanding without altering Venrock's fully diluted stake. The filing also details Q2 2026 financials: $137.9 million in cash, a net loss of $18.9 million, and a cash runway into the second half of 2028. On the pipeline front, EMA Orphan Drug Designation for KRRO-121 and the nomination of KRRO-111 for AATD both signal positive momentum for the company's clinical trajectory.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KRRO was trading at $11.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $165.9M. The 52-week trading range was $5.20 to $55.89. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KRRO - Latest Insights

KRRO
Nov 05, 2026, 3:02 PM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $14.86
Real-time Price: $12.31 info
Change: -$2.55 (-17%) info
Market Cap: $169.1M info
KRRO
Nov 05, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $16.29
Real-time Price: $12.31 info
Change: -$3.98 (-24%) info
Market Cap: $169.1M info
KRRO
Oct 26, 2026, 6:37 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $12.02
Real-time Price: $12.31 info
Change: +$0.290 (+2%) info
Market Cap: $169.1M info
KRRO
Oct 22, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.35
Real-time Price: $12.31 info
Change: +$2.96 (+32%) info
Market Cap: $169.1M info
KRRO
Oct 22, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $9.35
Real-time Price: $12.31 info
Change: +$2.96 (+32%) info
Market Cap: $169.1M info